These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 26189041

  • 1. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
    Gu L, Xie L, Zuo C, Ma Z, Zhang Y, Zhu Y, Gao J.
    BMC Cancer; 2015 Jul 20; 15():529. PubMed ID: 26189041
    [Abstract] [Full Text] [Related]

  • 2. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
    Gu L, Gao J, Li Q, Zhu YP, Jia CS, Fu RY, Chen Y, Liao QK, Ma Z.
    Leukemia; 2008 Nov 20; 22(11):2091-6. PubMed ID: 18685609
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J, Zhang L, Zhang X, Xing X.
    J Chemother; 2015 Nov 20; 27(6):358-64. PubMed ID: 25976336
    [Abstract] [Full Text] [Related]

  • 4. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.
    Gu L, Zhou C, Liu H, Gao J, Li Q, Mu D, Ma Z.
    J Exp Clin Cancer Res; 2010 Nov 18; 29(1):150. PubMed ID: 21083937
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
    Guo X, Zhou CY, Li Q, Gao J, Zhu YP, Gu L, Ma ZG.
    Biomed Environ Sci; 2013 May 18; 26(5):371-81. PubMed ID: 23611130
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells.
    Jiang L, Xu L, Xie J, Li S, Guan Y, Zhang Y, Hou Z, Guo T, Shu X, Wang C, Fan W, Si Y, Yang Y, Kang Z, Fang M, Liu Q.
    Cancer Biol Ther; 2015 May 18; 16(3):466-76. PubMed ID: 25778879
    [Abstract] [Full Text] [Related]

  • 7. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD, Nien WL, Dauphinee SM, Too CK.
    J Endocrinol; 2006 Aug 18; 190(2):307-12. PubMed ID: 16899564
    [Abstract] [Full Text] [Related]

  • 8. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells].
    Zhang YJ, Fang JY, Sun DF, Zhao SL, Shen GF, Zheng Q, Zhu HY.
    Zhonghua Zhong Liu Za Zhi; 2007 Dec 18; 29(12):889-93. PubMed ID: 18478925
    [Abstract] [Full Text] [Related]

  • 9. [Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].
    Zhou LH, Zhu XP, Xiao HF, Xin PL, Li CT.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct 18; 25(5):1397-1405. PubMed ID: 29070114
    [Abstract] [Full Text] [Related]

  • 10. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.
    Cancer Res; 2006 Feb 15; 66(4):2305-13. PubMed ID: 16489035
    [Abstract] [Full Text] [Related]

  • 11. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.
    Strömberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, Jernberg-Wiklund H.
    Blood; 2004 Apr 15; 103(8):3138-47. PubMed ID: 15070696
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H.
    Leuk Res; 2007 May 15; 31(5):673-82. PubMed ID: 17007924
    [Abstract] [Full Text] [Related]

  • 13. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF.
    Clin Cancer Res; 2009 Mar 01; 15(5):1708-20. PubMed ID: 19223503
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.
    Li H, Kong X, Cui G, Ren C, Fan S, Sun L, Zhang Y, Cao R, Li Y, Zhou J.
    Int J Hematol; 2015 Nov 01; 102(5):558-68. PubMed ID: 26362858
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, Chen SJ, Zhao WL.
    J Hematol Oncol; 2013 Jul 18; 6():53. PubMed ID: 23866964
    [Abstract] [Full Text] [Related]

  • 18. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
    Chang Q, Chen E, Hedley DW.
    Cancer Biol Ther; 2009 Oct 18; 8(20):1893-901. PubMed ID: 20009539
    [Abstract] [Full Text] [Related]

  • 19. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
    Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P.
    Leukemia; 2005 Dec 18; 19(12):2153-8. PubMed ID: 16193082
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J, Xue L, Hao H, Han Y, Yang J, Luo J.
    Oncol Rep; 2012 Feb 18; 27(2):461-6. PubMed ID: 21993902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.